MedPath
HSA Approval

INHIXA Solution for Injection 4000 Anti-Xa IU (40MG)/0.4ML

SIN16998P

INHIXA Solution for Injection 4000 Anti-Xa IU (40MG)/0.4ML

INHIXA Solution for Injection 4000 Anti-Xa IU (40MG)/0.4ML

May 7, 2024

PHARMAZEN MEDICALS PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAZEN MEDICALS PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

SUBCUTANEOUS, INTRAVENOUS BOLUS

Medical Information

B01AB05

Manufacturer Information

PHARMAZEN MEDICALS PTE LTD

Shenzhen Techdow Pharmaceutical Co., Ltd.

Active Ingredients

Enoxaparin Sodium

4000 IU (40 MG)/0.4 ML

Enoxaparin sodium

Documents

Package Inserts

Inhixa Solution for Injection PI.pdf

Approved: May 7, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

INHIXA Solution for Injection 4000 Anti-Xa IU (40MG)/0.4ML - HSA Approval | MedPath